Henlius Finds Global Partner For Ophthalmic Bevacizumab
Strikes Deal With Essex Bio-Technology For Biosimilar Avastin Rival
Executive Summary
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.
You may also be interested in...
Asia Deal Watch: CStone Partners With LegoChem On Novel ADC Candidate
Plus deals involving Lilly/Daiichi Sankyo, Humianigen/KPM Tech, Telix/China Grand, Appili/Fujifilm, BioInvent/CASI, Osotec/Adel, Neumentum/Nuance, Takeda/HemoShear and Quantum Genomics/Qilu.
Accord And Henlius Broaden Trastuzumab Alliance
Shanghai Henlius Biotech and Accord Healthcare have broadened their collaboration on trastuzumab, with the Chinese company licensing its Zercepac biosimilar to Accord in the US and Canada. Meanwhile, Accord has launched a Pelgraz pegfilgrastim pre-filled injector and patient app in the UK.
China Sees Flurry Of Activity On Avastin
An approval for Innovent’s bevacizumab biosimilar has been granted in China, while other potential rivals to Avastin in the region have hit development milestones.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: